Hoosiers introduce anti-compounding bill … and it’s a mess

A couple of members of Congress from Eli Lilly’s home state of Indiana have introduced a bill they say is meant to protect patients, but it’s based on pharma’s talking points. In reality, it’s more about limiting legitimate compounding.

Congressmen Rudy Yakym and André Carson of Indiana introduced what they call the “Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.” It’s essentially an anti-compounding bill straight out of the drugmakers’ playbook — it even uses the same tired, unfounded arguments. (Not a surprise, considering they quoted the executive director of the pharma puppet group Partnership for Safe Medicines in their press release.)

Essentially, it would prohibit non-hospital pharmacies from compounding more than 20 times in a month “any drug product that is essentially a copy of a commercially available drug product” without submitting a report to the FDA. (Here’s the full text — 6-page PDF.)

Another bit of wording implies that the congressmen don’t know how compounding works. The bill, you see, defines “essentially a copy” as ‘a compounded drug that doesn’t produce a significant difference for the patient from the commercially available drug product as determined by the prescriber.’ But if it didn’t produce a significant difference, the prescriber wouldn’t have prescribed it in the first place!

In short, aside from increasing some inspections of 503B outsourcing facilities, the entire bill seems to be full of sound and fury, but signifying nothing. Still, the fact that such a bill was even introduced is a reminder that our work calling out pharma’s “misinformation” doesn’t end.